466 related articles for article (PubMed ID: 32238376)
1. CGRP antagonists for decreasing migraine frequency: New options, long overdue.
Bucklan J; Ahmed Z
Cleve Clin J Med; 2020 Apr; 87(4):211-218. PubMed ID: 32238376
[TBL] [Abstract][Full Text] [Related]
2. History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment.
Tepper SJ
Headache; 2018 Nov; 58 Suppl 3():238-275. PubMed ID: 30242830
[TBL] [Abstract][Full Text] [Related]
3. European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention.
Sacco S; Bendtsen L; Ashina M; Reuter U; Terwindt G; Mitsikostas DD; Martelletti P
J Headache Pain; 2019 Jan; 20(1):6. PubMed ID: 30651064
[TBL] [Abstract][Full Text] [Related]
4. Migraine therapeutics differentially modulate the CGRP pathway.
Bhakta M; Vuong T; Taura T; Wilson DS; Stratton JR; Mackenzie KD
Cephalalgia; 2021 Apr; 41(5):499-514. PubMed ID: 33626922
[TBL] [Abstract][Full Text] [Related]
5. CGRP Antibodies as Prophylaxis in Migraine.
Edvinsson L
Cell; 2018 Dec; 175(7):1719. PubMed ID: 30550780
[TBL] [Abstract][Full Text] [Related]
6. Network meta-analysis on efficacy and safety of different anti-CGRP monoclonal antibody regimens for prophylaxis and treatment of episodic migraine.
Shi M; Guo J; Li Z; Sun H; Yang X; Yang D; Zhao H
Neurol Res; 2021 Nov; 43(11):932-949. PubMed ID: 34281473
[TBL] [Abstract][Full Text] [Related]
7. Calcitonin gene-related peptide (CGRP)-targeted therapies as preventive and acute treatments for migraine-The monoclonal antibodies and gepants.
Chiang CC; Schwedt TJ
Prog Brain Res; 2020; 255():143-170. PubMed ID: 33008505
[TBL] [Abstract][Full Text] [Related]
8. Medications Approved for Preventing Migraine Headaches.
Spindler BL; Ryan M
Am J Med; 2020 Jun; 133(6):664-667. PubMed ID: 32145209
[TBL] [Abstract][Full Text] [Related]
9. CGRP as the target of new migraine therapies - successful translation from bench to clinic.
Edvinsson L; Haanes KA; Warfvinge K; Krause DN
Nat Rev Neurol; 2018 Jun; 14(6):338-350. PubMed ID: 29691490
[TBL] [Abstract][Full Text] [Related]
10. Role of Monoclonal Antibodies against Calcitonin Gene-Related Peptide (CGRP) in Episodic Migraine Prevention: Where Do We Stand Today?
Nagaraj K; Vandenbussche N; Goadsby PJ
Neurol India; 2021; 69(Supplement):S59-S66. PubMed ID: 34003149
[TBL] [Abstract][Full Text] [Related]
11. A new era for migraine: Pharmacokinetic and pharmacodynamic insights into monoclonal antibodies with a focus on galcanezumab, an anti-CGRP antibody.
Kielbasa W; Helton DL
Cephalalgia; 2019 Sep; 39(10):1284-1297. PubMed ID: 30917684
[TBL] [Abstract][Full Text] [Related]
12. Monoclonal antibodies as a preventive therapy for migraine: A meta-analysis.
Alasad YW; Asha MZ
Clin Neurol Neurosurg; 2020 Aug; 195():105900. PubMed ID: 32460120
[TBL] [Abstract][Full Text] [Related]
13. Safety and tolerability of calcitonin-gene-related peptide binding monoclonal antibodies for the prevention of episodic migraine - a meta-analysis of randomized controlled trials.
Xu D; Chen D; Zhu LN; Tan G; Wang HJ; Zhang Y; Liu L
Cephalalgia; 2019 Aug; 39(9):1164-1179. PubMed ID: 30789292
[TBL] [Abstract][Full Text] [Related]
14. Raynaud's Phenomenon Associated With Calcitonin Gene-Related Peptide Monoclonal Antibody Antagonists.
Evans RW
Headache; 2019 Sep; 59(8):1360-1364. PubMed ID: 31310337
[TBL] [Abstract][Full Text] [Related]
15. An observational study on monoclonal antibodies against calcitonin-gene-related peptide and its receptor.
Schiano di Cola F; Bolchini M; Ceccardi G; Caratozzolo S; Liberini P; Rao R; Padovani A
Eur J Neurol; 2023 Jun; 30(6):1764-1773. PubMed ID: 36856538
[TBL] [Abstract][Full Text] [Related]
16. Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine.
Berman G; Croop R; Kudrow D; Halverson P; Lovegren M; Thiry AC; Conway CM; Coric V; Lipton RB
Headache; 2020 Sep; 60(8):1734-1742. PubMed ID: 32799325
[TBL] [Abstract][Full Text] [Related]
17. Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: An American Headache Society position statement update.
Charles AC; Digre KB; Goadsby PJ; Robbins MS; Hershey A;
Headache; 2024 Apr; 64(4):333-341. PubMed ID: 38466028
[TBL] [Abstract][Full Text] [Related]
18. [Anti-calcitonin generelated peptide (CGRP) therapies for migraine].
Moisset X; Demarquay G
Rev Prat; 2023 Feb; 73(2):123-126. PubMed ID: 36916250
[TBL] [Abstract][Full Text] [Related]
19. The Biology of Monoclonal Antibodies: Focus on Calcitonin Gene-Related Peptide for Prophylactic Migraine Therapy.
Raffaelli B; Reuter U
Neurotherapeutics; 2018 Apr; 15(2):324-335. PubMed ID: 29616494
[TBL] [Abstract][Full Text] [Related]
20. The CGRP Pathway in Migraine as a Viable Target for Therapies.
Edvinsson L
Headache; 2018 May; 58 Suppl 1():33-47. PubMed ID: 29697153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]